In this study cohort of NSCLC patients, UFT did not affect the anti-S1 antibody titers after COVID-19 vaccination, temporary discontinuation of UFT therapy did not affect the anti-S1 antibody titers after COVID-19 vaccination, and no severe adverse events ( ≥ Grade 3 in CTCAE v5.0) occurred. Here, PSMD1 is linked to non-small cell lung carcinoma.